Pharmacokinetics of alectinib and its metabolite M4 in a patient with advanced lung adenocarcinoma undergoing hemodialysis: A case report

Abstract This study presents the first detailed pharmacokinetic data of alectinib and its metabolite M4 in a patient with anaplastic lymphoma kinase (ALK)‐rearranged lung adenocarcinoma undergoing hemodialysis. When the patient was administered a daily 300 mg bid dose of alectinib, the maximal obser...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Ji Eun Park, Young‐Ran Yoon, Chang Ho Kim, Jaehee Lee
Materialtyp: Artigo
Språk:Inglês
Publicerad: Wiley 2022-04-01
Serie:Thoracic Cancer
Ämnen:
alectinib
ALK rearrangement
lung cancer
M4
pharmacokinetics
Länkar:https://doi.org/10.1111/1759-7714.14357
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk